pembrolizumab
merck
['biomarker', 'pembro']
very exited to present for the first time in asco the results on clinical data &amp; circulating biomarker of phase ii people trial, by looking at io benefit in first line sign agent pembrolizumab in low pd-l1 patients 
Medical Oncologist, Fondazione IRCCS Istituto Nazionale dei Tumori di https://t.co/iiS6Ae62fN student in Bioengineering and Artificial Intelligente, Politecnico di Milano